The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer

Abstract

Purpose: There is a clear need to improve risk stratification and to identify novel therapeutic targets in aggressive prostate cancer. The goal of this study was to investigate genes with outlier expression with prognostic association in high-risk prostate cancer patients as potential biomarkers and drug targets.Experimental Design: We interrogated microarray gene expression data from prostatectomy samples from 545 high-risk prostate cancer patients with long-term follow-up (mean 13.4 years). Three independent clinical datasets totaling an additional 545 patients were used for validation. Novel prognostic outlier genes were interrogated for impact on oncogenic phenotypes in vitro using siRNA-based knockdown. Association with clinical outcomes and comparison with existing prognostic instruments was assessed with multivariable models using a prognostic outlier score.Results: Analysis of the discovery cohort identified 20 prognostic outlier genes. Three top prognostic outlier genes were novel prostate cancer genes; NVL, SMC4, or SQLE knockdown reduced migration and/or invasion and outlier expression was significantly associated with poor prognosis. Increased prognostic outlier score was significantly associated with poor prognosis independent of standard clinicopathologic variables. Finally, the prognostic outlier score prognostic association is independent of, and adds to existing genomic and clinical tools for prognostication in prostate cancer (Decipher, the cell-cycle progression signature, and CAPRA-S).Conclusions: To our knowledge, this study represents the first unbiased high-throughput investigation of prognostic outlier genes in prostate cancer and demonstrates the potential biomarker and therapeutic importance of this previously unstudied class of cancer genes.

Prostate cancer biomarkers: Are we hitting the mark?

“…Clinically, Decipher has undergone multiple validation studies with a total of > 2,000 patients and an AUC of 0.79. Patients who were deemed high risk with Decipher (GC ≥ 0.4) and received adjuvant therapy had improved survival 3, 36, 37, 38. Klein et al 36 evaluated the use of the Decipher GC with the National Comprehensive Cancer Network on 57 patients from a previous Decipher validation study from Cleveland Clinic.…”

Identification and Prognostic Analysis of Hub Genes in Bladder Cancer

“…Structural maintenance of chromosome 4 (SMC4) is a core subunit of condensin complexes, which chie y involved in chromosome condensation and segregation 49 . Overexpression of SMC4 is related to tumorigenesis and involved in tumor cell cycle, migration and invasion 50 .Previous studies have shown that SMC4 protein is highly increased in various tumors and correlated with poor prognosis of cancer patient [51][52][53][54][55] . However, its clinical signi cance and functional role in BC remain unknown.…”

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors

“…High levels of FAM83D have been associated with poor outcome in several tumors and an increase in proliferation in vitro models [9, 10]. SMC4 belongs to a family of genes linked with poor outcome in prostate cancer [11], and finally, GTSE1 was described as associated with worse prognosis in uterine leimyosarcoma [12]. …”